Bone-Targeted Therapies in Cancer-Induced Bone Disease
Cancer-induced bone disease is a major source of morbidity and mortality in cancer patients. Thus, effective bone-targeted therapies are essential to improve disease-free, overall survival and quality of life of cancer patients with bone metastases. Depending of the cancer-type, bone metastases main...
Gespeichert in:
Veröffentlicht in: | Calcified tissue international 2018-02, Vol.102 (2), p.227-250 |
---|---|
Hauptverfasser: | , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 250 |
---|---|
container_issue | 2 |
container_start_page | 227 |
container_title | Calcified tissue international |
container_volume | 102 |
creator | Sousa, Sofia Clézardin, Philippe |
description | Cancer-induced bone disease is a major source of morbidity and mortality in cancer patients. Thus, effective bone-targeted therapies are essential to improve disease-free, overall survival and quality of life of cancer patients with bone metastases. Depending of the cancer-type, bone metastases mainly involve the modulation of osteoclast and/or osteoblast activity by tumour cells. To inhibit metastatic bone disease effectively, it is imperative to understand its underlying mechanisms and identify the target cells for therapy. If the aim is to prevent bone metastasis, it is essential to target not only bone metastatic features in the tumour cells, but also tumour-nurturing bone microenvironment properties. The currently available bone-targeted agents mainly affect osteoclasts, inhibiting bone resorption (e.g. bisphosphonates, denosumab). Some agents targeting osteoblasts begin to emerge which target osteoblasts (e.g. romosozumab), activating bone formation. Moreover, certain drugs initially thought to target only osteoclasts are now known to have a dual action (activating osteoblasts and inhibiting osteoclasts, e.g. proteasome inhibitors). This review will focus on the evolution of bone-targeted therapies for the treatment of cancer-induced bone disease, summarizing preclinical and clinical findings obtained with anti-resorptive and bone anabolic therapies. |
doi_str_mv | 10.1007/s00223-017-0353-5 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1957492876</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1957492876</sourcerecordid><originalsourceid>FETCH-LOGICAL-c415t-8a66f8ae36d317146295113cc4a03d63fb2ea243600ef3090244d2339ba285473</originalsourceid><addsrcrecordid>eNp1kD1PwzAQhi0EoqXwA1hQJBYWw_k7HqF8VarEUiQ2y00uJVWbFLsZ-Pe4SkEIicnD-9zru4eQcwbXDMDcRADOBQVmKAglqDogQyYFp5Bzc0iGKWDUavM2ICcxLgGY1FofkwG3YKy1akj0XdsgnfmwwC2W2ewdg9_UGLO6yca-KTDQSVN2Rcp2ZHZfR_QRT8lR5VcRz_bviLw-PszGz3T68jQZ305pIZna0txrXeUehS5F2kVqbhVjoiikB1FqUc05ei6FBsBKgAUuZcmFsHPPcyWNGJGrvncT2o8O49at61jgauUbbLvomFVGWp4bndDLP-iy7UKTtktUuhVylvNEsZ4qQhtjwMptQr324dMxcDuprpfqkju3k-pUmrnYN3fzNZY_E98WE8B7IKaoWWD49fW_rV9Ak330</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1999508182</pqid></control><display><type>article</type><title>Bone-Targeted Therapies in Cancer-Induced Bone Disease</title><source>MEDLINE</source><source>Springer Online Journals Complete</source><creator>Sousa, Sofia ; Clézardin, Philippe</creator><creatorcontrib>Sousa, Sofia ; Clézardin, Philippe</creatorcontrib><description>Cancer-induced bone disease is a major source of morbidity and mortality in cancer patients. Thus, effective bone-targeted therapies are essential to improve disease-free, overall survival and quality of life of cancer patients with bone metastases. Depending of the cancer-type, bone metastases mainly involve the modulation of osteoclast and/or osteoblast activity by tumour cells. To inhibit metastatic bone disease effectively, it is imperative to understand its underlying mechanisms and identify the target cells for therapy. If the aim is to prevent bone metastasis, it is essential to target not only bone metastatic features in the tumour cells, but also tumour-nurturing bone microenvironment properties. The currently available bone-targeted agents mainly affect osteoclasts, inhibiting bone resorption (e.g. bisphosphonates, denosumab). Some agents targeting osteoblasts begin to emerge which target osteoblasts (e.g. romosozumab), activating bone formation. Moreover, certain drugs initially thought to target only osteoclasts are now known to have a dual action (activating osteoblasts and inhibiting osteoclasts, e.g. proteasome inhibitors). This review will focus on the evolution of bone-targeted therapies for the treatment of cancer-induced bone disease, summarizing preclinical and clinical findings obtained with anti-resorptive and bone anabolic therapies.</description><identifier>ISSN: 0171-967X</identifier><identifier>EISSN: 1432-0827</identifier><identifier>DOI: 10.1007/s00223-017-0353-5</identifier><identifier>PMID: 29079995</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Androgen Antagonists - therapeutic use ; Biochemistry ; Biomedical and Life Sciences ; Bisphosphonates ; Bone cancer ; Bone diseases ; Bone growth ; Bone Neoplasms - drug therapy ; Bone Neoplasms - secondary ; Bone resorption ; Bortezomib - therapeutic use ; Cancer ; Cancer therapies ; Cathepsin K - antagonists & inhibitors ; Cell Biology ; Denosumab - therapeutic use ; Diphosphonates - therapeutic use ; Endocrinology ; Humans ; Immunotherapy ; Integrins - antagonists & inhibitors ; Life Sciences ; Metastases ; Metastasis ; Molecular Targeted Therapy ; Monoclonal antibodies ; Morbidity ; Orthopedics ; Osteoblasts ; Osteoclasts ; Osteogenesis ; Proteasome inhibitors ; Proteasome Inhibitors - therapeutic use ; Proto-Oncogene Proteins pp60(c-src) - antagonists & inhibitors ; Quality of life ; Radiopharmaceuticals - therapeutic use ; Review ; Targeted cancer therapy ; TOR Serine-Threonine Kinases - antagonists & inhibitors ; Tumors</subject><ispartof>Calcified tissue international, 2018-02, Vol.102 (2), p.227-250</ispartof><rights>Springer Science+Business Media, LLC 2017</rights><rights>Calcified Tissue International is a copyright of Springer, (2017). All Rights Reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c415t-8a66f8ae36d317146295113cc4a03d63fb2ea243600ef3090244d2339ba285473</citedby><cites>FETCH-LOGICAL-c415t-8a66f8ae36d317146295113cc4a03d63fb2ea243600ef3090244d2339ba285473</cites><orcidid>0000-0002-4368-4866</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00223-017-0353-5$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00223-017-0353-5$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>315,781,785,27929,27930,41493,42562,51324</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29079995$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sousa, Sofia</creatorcontrib><creatorcontrib>Clézardin, Philippe</creatorcontrib><title>Bone-Targeted Therapies in Cancer-Induced Bone Disease</title><title>Calcified tissue international</title><addtitle>Calcif Tissue Int</addtitle><addtitle>Calcif Tissue Int</addtitle><description>Cancer-induced bone disease is a major source of morbidity and mortality in cancer patients. Thus, effective bone-targeted therapies are essential to improve disease-free, overall survival and quality of life of cancer patients with bone metastases. Depending of the cancer-type, bone metastases mainly involve the modulation of osteoclast and/or osteoblast activity by tumour cells. To inhibit metastatic bone disease effectively, it is imperative to understand its underlying mechanisms and identify the target cells for therapy. If the aim is to prevent bone metastasis, it is essential to target not only bone metastatic features in the tumour cells, but also tumour-nurturing bone microenvironment properties. The currently available bone-targeted agents mainly affect osteoclasts, inhibiting bone resorption (e.g. bisphosphonates, denosumab). Some agents targeting osteoblasts begin to emerge which target osteoblasts (e.g. romosozumab), activating bone formation. Moreover, certain drugs initially thought to target only osteoclasts are now known to have a dual action (activating osteoblasts and inhibiting osteoclasts, e.g. proteasome inhibitors). This review will focus on the evolution of bone-targeted therapies for the treatment of cancer-induced bone disease, summarizing preclinical and clinical findings obtained with anti-resorptive and bone anabolic therapies.</description><subject>Androgen Antagonists - therapeutic use</subject><subject>Biochemistry</subject><subject>Biomedical and Life Sciences</subject><subject>Bisphosphonates</subject><subject>Bone cancer</subject><subject>Bone diseases</subject><subject>Bone growth</subject><subject>Bone Neoplasms - drug therapy</subject><subject>Bone Neoplasms - secondary</subject><subject>Bone resorption</subject><subject>Bortezomib - therapeutic use</subject><subject>Cancer</subject><subject>Cancer therapies</subject><subject>Cathepsin K - antagonists & inhibitors</subject><subject>Cell Biology</subject><subject>Denosumab - therapeutic use</subject><subject>Diphosphonates - therapeutic use</subject><subject>Endocrinology</subject><subject>Humans</subject><subject>Immunotherapy</subject><subject>Integrins - antagonists & inhibitors</subject><subject>Life Sciences</subject><subject>Metastases</subject><subject>Metastasis</subject><subject>Molecular Targeted Therapy</subject><subject>Monoclonal antibodies</subject><subject>Morbidity</subject><subject>Orthopedics</subject><subject>Osteoblasts</subject><subject>Osteoclasts</subject><subject>Osteogenesis</subject><subject>Proteasome inhibitors</subject><subject>Proteasome Inhibitors - therapeutic use</subject><subject>Proto-Oncogene Proteins pp60(c-src) - antagonists & inhibitors</subject><subject>Quality of life</subject><subject>Radiopharmaceuticals - therapeutic use</subject><subject>Review</subject><subject>Targeted cancer therapy</subject><subject>TOR Serine-Threonine Kinases - antagonists & inhibitors</subject><subject>Tumors</subject><issn>0171-967X</issn><issn>1432-0827</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp1kD1PwzAQhi0EoqXwA1hQJBYWw_k7HqF8VarEUiQ2y00uJVWbFLsZ-Pe4SkEIicnD-9zru4eQcwbXDMDcRADOBQVmKAglqDogQyYFp5Bzc0iGKWDUavM2ICcxLgGY1FofkwG3YKy1akj0XdsgnfmwwC2W2ewdg9_UGLO6yca-KTDQSVN2Rcp2ZHZfR_QRT8lR5VcRz_bviLw-PszGz3T68jQZ305pIZna0txrXeUehS5F2kVqbhVjoiikB1FqUc05ei6FBsBKgAUuZcmFsHPPcyWNGJGrvncT2o8O49at61jgauUbbLvomFVGWp4bndDLP-iy7UKTtktUuhVylvNEsZ4qQhtjwMptQr324dMxcDuprpfqkju3k-pUmrnYN3fzNZY_E98WE8B7IKaoWWD49fW_rV9Ak330</recordid><startdate>20180201</startdate><enddate>20180201</enddate><creator>Sousa, Sofia</creator><creator>Clézardin, Philippe</creator><general>Springer US</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QP</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-4368-4866</orcidid></search><sort><creationdate>20180201</creationdate><title>Bone-Targeted Therapies in Cancer-Induced Bone Disease</title><author>Sousa, Sofia ; Clézardin, Philippe</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c415t-8a66f8ae36d317146295113cc4a03d63fb2ea243600ef3090244d2339ba285473</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Androgen Antagonists - therapeutic use</topic><topic>Biochemistry</topic><topic>Biomedical and Life Sciences</topic><topic>Bisphosphonates</topic><topic>Bone cancer</topic><topic>Bone diseases</topic><topic>Bone growth</topic><topic>Bone Neoplasms - drug therapy</topic><topic>Bone Neoplasms - secondary</topic><topic>Bone resorption</topic><topic>Bortezomib - therapeutic use</topic><topic>Cancer</topic><topic>Cancer therapies</topic><topic>Cathepsin K - antagonists & inhibitors</topic><topic>Cell Biology</topic><topic>Denosumab - therapeutic use</topic><topic>Diphosphonates - therapeutic use</topic><topic>Endocrinology</topic><topic>Humans</topic><topic>Immunotherapy</topic><topic>Integrins - antagonists & inhibitors</topic><topic>Life Sciences</topic><topic>Metastases</topic><topic>Metastasis</topic><topic>Molecular Targeted Therapy</topic><topic>Monoclonal antibodies</topic><topic>Morbidity</topic><topic>Orthopedics</topic><topic>Osteoblasts</topic><topic>Osteoclasts</topic><topic>Osteogenesis</topic><topic>Proteasome inhibitors</topic><topic>Proteasome Inhibitors - therapeutic use</topic><topic>Proto-Oncogene Proteins pp60(c-src) - antagonists & inhibitors</topic><topic>Quality of life</topic><topic>Radiopharmaceuticals - therapeutic use</topic><topic>Review</topic><topic>Targeted cancer therapy</topic><topic>TOR Serine-Threonine Kinases - antagonists & inhibitors</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sousa, Sofia</creatorcontrib><creatorcontrib>Clézardin, Philippe</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Calcified tissue international</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sousa, Sofia</au><au>Clézardin, Philippe</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Bone-Targeted Therapies in Cancer-Induced Bone Disease</atitle><jtitle>Calcified tissue international</jtitle><stitle>Calcif Tissue Int</stitle><addtitle>Calcif Tissue Int</addtitle><date>2018-02-01</date><risdate>2018</risdate><volume>102</volume><issue>2</issue><spage>227</spage><epage>250</epage><pages>227-250</pages><issn>0171-967X</issn><eissn>1432-0827</eissn><abstract>Cancer-induced bone disease is a major source of morbidity and mortality in cancer patients. Thus, effective bone-targeted therapies are essential to improve disease-free, overall survival and quality of life of cancer patients with bone metastases. Depending of the cancer-type, bone metastases mainly involve the modulation of osteoclast and/or osteoblast activity by tumour cells. To inhibit metastatic bone disease effectively, it is imperative to understand its underlying mechanisms and identify the target cells for therapy. If the aim is to prevent bone metastasis, it is essential to target not only bone metastatic features in the tumour cells, but also tumour-nurturing bone microenvironment properties. The currently available bone-targeted agents mainly affect osteoclasts, inhibiting bone resorption (e.g. bisphosphonates, denosumab). Some agents targeting osteoblasts begin to emerge which target osteoblasts (e.g. romosozumab), activating bone formation. Moreover, certain drugs initially thought to target only osteoclasts are now known to have a dual action (activating osteoblasts and inhibiting osteoclasts, e.g. proteasome inhibitors). This review will focus on the evolution of bone-targeted therapies for the treatment of cancer-induced bone disease, summarizing preclinical and clinical findings obtained with anti-resorptive and bone anabolic therapies.</abstract><cop>New York</cop><pub>Springer US</pub><pmid>29079995</pmid><doi>10.1007/s00223-017-0353-5</doi><tpages>24</tpages><orcidid>https://orcid.org/0000-0002-4368-4866</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0171-967X |
ispartof | Calcified tissue international, 2018-02, Vol.102 (2), p.227-250 |
issn | 0171-967X 1432-0827 |
language | eng |
recordid | cdi_proquest_miscellaneous_1957492876 |
source | MEDLINE; Springer Online Journals Complete |
subjects | Androgen Antagonists - therapeutic use Biochemistry Biomedical and Life Sciences Bisphosphonates Bone cancer Bone diseases Bone growth Bone Neoplasms - drug therapy Bone Neoplasms - secondary Bone resorption Bortezomib - therapeutic use Cancer Cancer therapies Cathepsin K - antagonists & inhibitors Cell Biology Denosumab - therapeutic use Diphosphonates - therapeutic use Endocrinology Humans Immunotherapy Integrins - antagonists & inhibitors Life Sciences Metastases Metastasis Molecular Targeted Therapy Monoclonal antibodies Morbidity Orthopedics Osteoblasts Osteoclasts Osteogenesis Proteasome inhibitors Proteasome Inhibitors - therapeutic use Proto-Oncogene Proteins pp60(c-src) - antagonists & inhibitors Quality of life Radiopharmaceuticals - therapeutic use Review Targeted cancer therapy TOR Serine-Threonine Kinases - antagonists & inhibitors Tumors |
title | Bone-Targeted Therapies in Cancer-Induced Bone Disease |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-15T07%3A06%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Bone-Targeted%20Therapies%20in%20Cancer-Induced%20Bone%20Disease&rft.jtitle=Calcified%20tissue%20international&rft.au=Sousa,%20Sofia&rft.date=2018-02-01&rft.volume=102&rft.issue=2&rft.spage=227&rft.epage=250&rft.pages=227-250&rft.issn=0171-967X&rft.eissn=1432-0827&rft_id=info:doi/10.1007/s00223-017-0353-5&rft_dat=%3Cproquest_cross%3E1957492876%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1999508182&rft_id=info:pmid/29079995&rfr_iscdi=true |